ASCO: Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy by Subtype

In a study presented at ASCO, a team of researchers used microarrays to characterize 130 triple-negative breast cancer patients treated with neoadjuvant chemotherapy to see whether certain subtypes are more likely to respond to the treatment.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news